Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To understand 295 gene mutation mutation status (include EGFR, HER2, KRAS, BRAF, PIK3CA,ect) by deep sequencing in Chinese patients with pulmonary adenocarcinoma and their relationships with the patients' clinical features (including sex, age, smoking history and adenocarcinoma subtype), specify the predictive significance of the genes mutations for new targeted therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to EGFR-TKIs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781

Non-Small Cell Lung Cancer

COMPLETED

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141

Nonsmall Cell Lung Cancer

UNKNOWN

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

NCT02623257

Non-small Cell Lung Cancer Stage III Non-Small-Cell Lung Cancer Metastatic

COMPLETED

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

NCT02618590

Non-Small Cell Lung Cancer

UNKNOWN

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NCT03609918

NSCLC

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is prospective to identify biomarkers to resistant to afatinib，gefitinib and erlotinib in non-small cell lung cancer patients. Mutations of whole exon of 295 gene are analysed by deep sequencing in Chinese patients with non-small cell lung cancer and their relationships with the patients' clinical features (including sex, age, smoking history and adenocarcinoma subtype), specify the predictive significance of the genes mutations for new targeted therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to EGFR-TKIs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\>18 years,both male and female
* Histologically confirmed patients with pulmonary adenocarcinoma (Stage I-IV)
* ECOG 0-2
* Patients with enough paraffin tissue specimens or fresh tissue for detection
* Quality of the DNA extracted from the tissue samples ensures that the DNA can be used in DNA sequencing
* Subjects who provide detailed clinical and follow-up information

Exclusion Criteria

* Patients with other tumors
* Patients suffering from other serious diseases like infectious diseases (viral hepatitis, HIV,etc)
* Pregnant women shall be excluded

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No